Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite

AIMS: This study reports the pharmacokinetics of nelfinavir, its active metabolite, M8, and active moiety (nelfinavir + M8) in volunteers genotyped for CYP2C19 as extensive metabolizer (*1*1; n = 38), heterozygous poor metabolizer (PM) (*1*2; n = 22) and homozygous PM (*2*2; n = 6). METHODS: Subject...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Damle, Bharat D, Uderman, Howard, Biswas, Pinaki, Crownover, Penelope, Lin, Chang, Glue, Paul
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2009
Matèries:
Pharmacokinetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2791974/
https://ncbi.nlm.nih.gov/pubmed/19916992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2009.03499.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars